Inactive Instrument

Press Releases Fibrocell Science Inc Nasdaq

Equities

US3157213089

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Fibrocell Science : Castle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science	19-12-17	AQ
FIBROCELL SCIENCE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	19-12-13	AQ
FIBROCELL SCIENCE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	19-12-10	AQ
FIBROCELL SCIENCE, INC. : Other Events (form 8-K)	19-11-22	AQ
FIBROCELL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fibrocell Science, Inc. - FCSC	19-09-17	BU
Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights	19-08-14	GL
Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB	19-05-29	GL
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy	19-04-15	GL
Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007	19-03-27	GL
Fibrocell to Present at 21st Annual BIO CEO & Investor Conference	19-02-06	GL
Fibrocell to Present at Phacilitate Leaders World 2019	19-01-16	GL
Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights	18-11-13	GL
Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third Quarter 2018 Financial Results and Recent Highlights	18-11-08	GL
Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007	18-10-25	GL
Fibrocell to Present at 20th Annual Rodman & Renshaw Global Investment Conference	18-08-29	GL
Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights	18-08-09	GL
Fibrocell Announces Closing of $4.0 Million Registered Direct Offering	18-07-05	GL
Fibrocell Announces $4.0 Million Registered Direct Offering Priced At-the-Market	18-07-02	GL
Fibrocell Announces Closing of $6.0 Million Registered Direct Offering	18-05-31	GL
Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market	18-05-29	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Fibrocell Science Inc Nasdaq

Equities

US3157213089

Press Releases

Filters